ArticleEuropean heart journal. Case reports2026
Cardiogenic shock and atrial fibrillation after mavacamten dose escalation in obstructive hypertrophic cardiomyopathy: a case report.
Article in European heart journal. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mavacamten is a first-in-class cardiac myosin inhibitor (CMI) that reduces left ventricular outflow tract (LVOT) obstruction in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). However, excessive myosin inhibition may cause significant systolic dysfunction and rarely requires intensive care. Case summary: A 40-year-old woman with obstructive HCM presented with dyspnoea and palpitations. Mavacamten 5 mg daily improved symptoms after an inadequate response to β-blocker therapy, although significant LVOT obstruction persisted. Following dose escalation to 10 mg daily, her condition rapidly deteriorated, and she developed cardiogenic shock with severe biventricular systolic dysfunction and atrial fibrillation (AF) with a rapid ventricular response. Further history revealed recent alcohol consumption before the symptom exacerbation. She was admitted to the intensive care unit, mavacamten was discontinued, and intravenous amiodarone was initiated. Given the persistent haemodynamic instability and recent anticoagulation interruption, transoesophageal echocardiography was performed, identifying a large left atrial thrombus and precluding cardioversion. With therapeutic anticoagulation, rate control, and supportive care, sinus rhythm was spontaneously restored, and the left ventricular ejection fraction recovered to 50% within 5 days. At follow-up, systolic function had fully normalised. Low-dose mavacamten and β-blocker therapy were cautiously reintroduced, with reinforced counselling on alcohol abstinence and anticoagulation adherence. The patient remains clinically stable without recurrent ventricular dysfunction. Discussion: This case highlights that acute biventricular dysfunction may occur abruptly after CMI dose escalation, particularly when complicated by AF. Early recognition, prompt drug discontinuation, careful monitoring, and comprehensive patient education are essential for the safe clinical use of CMIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.